Kim J. Hasenkrug, Ph.D.Rocky Mountain LaboratoriesBuilding 3, Room 3210903 South 4th Street Hamilton, MT 59840-2932Phone: 406-363-9310Fax: firstname.lastname@example.org
Chief, Retroviral Immunology Section, LPVD
Our research is aimed at understanding host responses to retroviral infections. We use mice infected with Friend murine leukemia virus as a model to study basic immunology. A special interest is in chronic infections, including how chronic infections are established and maintained and developing strategies to prevent and treat them. Using this model, we discovered that viruses can subvert the suppressive nature of regulatory T cells to evade immunological destruction by CD8+ T cells. We also use “humanized” mice, mice that contain human immune systems, as a model to study immune responses to HIV infection and to help us determine basic mechanisms of vaccine protection against acute and chronic retroviral infections. The goal of these studies is to develop new ideas for HIV vaccines and therapies.
Dr. Hasenkrug received his Ph.D. in cell biology from the Albert Einstein College of Medicine in 1991 and conducted his postdoctoral research in the laboratory of Dr. Bruce Chesebro at the Rocky Mountain Laboratories. In 1998, he established an independent laboratory to study retroviral immunology and mechanisms of vaccine protection. A special focus of his work has been the study of establishment and maintenance of chronic infections and virus escape. Dr. Hasenkrug serves as an affiliated associate professor at Montana State University and the University of Montana and as a scientific advisor for the International AIDS Vaccine Initiative.
back to top
Lavender, Kerry J.. Pang, Wendy W., Messer, Ronald J., Duley, Amanda K., Race, Brent, Phillips, Katie, Scott, Dana, Peterson, Karin E., Chan, Charles K., Dittmer, Ulf, Dudek, Timothy, Allen, Todd M., Weissman, Irving L., and Hasenkrug, Kim J. BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/-mice are resistant to GVHD and develop B and T cell immunity to HIV infection. Blood (in press)
Myers, L., Joeicke, J.J., Carmody, A. B., Messer, R.J., Kassoitis, G., Dudley, Jaquelin, P., Dittmer, U., and Kim J. Hasenkrug. IL-2-independent and TNFα-dependent Expansion of Vβ5+ Natural Regulatory T Cells During Retrovirus Infection. Journal of Immunology 190: 5485-95, 2013
Duley, A. K., Ploquin, M. J., Eksmond, U., Ammann, C. G., Messer, R. J., Myers, L., Kassiotis, G., Hasenkrug, K. J. Negative impact of IFN-gamma on early host immune responses to retroviral infection. Journal of Immunology 189: 2521-9, 2012
Dietze, Kirsten K. , Gennadiy Zelinskyy, Kathrin Gibbert, Simone Schimmer, Sandra Francois, Lara Myers, Tim Sparwasser, Kim J Hasenkrug & Ulf Dittmer. Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral setpoints. Proceedings of the National Academy of Sciences (USA) 108:2420-5, 2011
Santiago, M. L., Montano, M., Benitez, R., Messer, R. J., Yonemoto, W., Chesebro, B., Hasenkrug, K. J.*, Greene, W. C.* (*shared senior authorship). Apobec3 encodes Rfv3, a gene influencing ne utralizing antibody control of retrovirus infection. Science 321: 1343-1346, 2008
Dittmer, Ulf, Hong He, Ronald J. Messer, Simone Schimmer, Anke R. M. Olbrich, Claes Ohlen, Philip D. Greenberg, Ingunn M. Stromnes, Michihiro Iwashiro, Shimon Sakaguchi, Leonard H. Evans, Karin E. Peterson, Guojun Yang, and Kim J. Hasenkrug. Functional impairment of CD8+ T cells by regulatory T cells during persistent retroviral infection. Immunity 20: 293-303 2004
Visit PubMed for a complete publication listing.
Last Updated October 26, 2012